Navigation Links
For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs

BURLINGTON, Mass., June 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that symptom control and quality of life is one of the factors the most influences surveyed U.S. and European oncologists' treatment decisions for second- and subsequent-line metastatic castrate-resistant prostate cancer (mCRPC), and that improved symptom control and quality of life is one of the greatest unmet needs in this indication. Interviewed thought leaders expressed optimism that cabozantinib (Exelixis's Cometriq) and radium-223 (Algeta/Bayer HealthCare's Xofigo) will have an advantage over sales-leading abiraterone (Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga) on this attribute and will help to partially fulfill the large unmet need.

(Logo: )

The DecisionBase 2013 report entitled Prostate Cancer (Second- and Subsequent-Line Metastatic Castrate-Resistant): What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Have to Offer in Order to Gain Traction in This Crowded and Competitive Market finds that surveyed U.S. managed care organization pharmacy directors are most willing to grant favorable formulary status to new second- and subsequent-line mCRPC therapies offering  increased median overall survival (MOS) over currently available treatment options. Nevertheless, nearly half of the surveyed payers indicated that they would not reimburse a new therapy priced the same as enzalutamide (Medivation/Astellas Pharma's Xtandi) or higher that offered a three-month improvement in median overall survival over enzalutamide, most commonly stating insufficient clinical benefit to grant reimbursement.     

The report also finds that surveyed U.S. oncologists would prescribe the emerging hormonal agent orteronel (Takeda/Millennium) to 25 percent of their second- and subsequent-line mCRPC patients - however, Decision Resources forecasts that orteronel will earn a more conservative patient share owing primarily to its late launch compared with its main competitors - abiraterone and enzalutamide - in the United States.

"Early-stage clinical data for orteronel are encouraging," said Decision Resources Senior Business Insight Analyst Dr. Karen Pomeranz . "Thought leaders are enthusiastic about hormonal therapies, in particular CYP17 inhibitors and state that they offer high efficacy and a more manageable safety and tolerability profile compared with that associated with standard chemotherapy. However, by the time orteronel will reach the market, the current hormonal therapies, abiraterone and enzalutamide, will have become well entrenched in the treatment algorithm for second- and subsequent-line mCRPC."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
2. Hospira to Host Conference Call for Second-quarter 2012 Results
3. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
4. Boston Scientific to Announce Second-Quarter 2012 Financial Results on July 26
5. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
6. Hospira Reports Second-Quarter 2012 Results
7. Star Scientific, Inc. Files Second-Quarter Financial Report (Net Sales and Gross Profits Continue to Increase) and Updates Research and Marketing Activities
8. WuXi PharmaTech Announces Second-Quarter 2012 Results
9. Cardinal Health Reports Fiscal 2013 Second-Quarter Results
10. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
11. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
Post Your Comments:
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare and ... , a country of over 122 million people. --> ... people. --> It offers companies, investors, policymakers, and stakeholders ... the second largest pharma and healthcare market in Latin ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology:
(Date:11/30/2015)... Viejo, CA (PRWEB) , ... November 30, 2015 , ... ... Cut Pro X . Choose from scrolling web-styled transitions to wipes with blur ... colors, transition direction and more. Seamlessly transition from one clip to the next ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... and Attendance/Workforce Management cloud-based solutions, announced today that it has renewed the ... the Application Development, demonstrating a “best-in-class” ability and commitment to meet Microsoft’s ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... to announce their strategic partnership at the Radiological Society of North America ... and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce their strategic partnership at the Radiological Society of North America (RSNA) ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
Breaking Medicine News(10 mins):